 Cardiovascular Business | FDA Reviewing Possible Heart Failure Risk with Pramipexole Family Practice News Digital Network Pramipexole, the dopamine agonist approved for treating Parkinson's disease and restless legs syndrome, may be associated with an increased risk for heart failure, according to a statement issued by the Food and Drug Administration. "Results of recent ... Parkinson's Drug Mirapex Under Safety Review FDA warns of potential heart failure risk with pramipexole Mirapex (pramipexole): Drug Safety Communication - Ongoing Safety Review ... |
